Nutraceuticals
News Releases
2023
December
November
Corporate
Otsuka Pharmaceutical to Sponsor Thematic Project "Resonance of Lives" at the Expo 2025 Osaka, Kansai, Japan
Pharmaceuticals
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
MIREVO®, a New Cognitive Function Testing Application for Dementia Care Support, Obtains Regulatory Approval, a First in Japan
Nutraceuticals
Selected as METI's "Model Project for the Promotion of PHR Services" Launch of a Healthcare Service that Improves Health without Conscious Effort
Corporate
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023 for LGBTQ+ Initiatives
Corporate
Otsuka Announces Personnel Changes
Pharmaceuticals
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
October
Pharmaceuticals
Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti® (brexpiprazole)
Corporate
Otsuka Pharmaceutical Receives Eruboshi Grade 3 Certification as an Excellent Company Under the Act on Promotion of Women's Participation and Advancement in the Workplace
Pharmaceuticals
Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Nutraceuticals
First PET Bottle and Paper Cup Recycling Initiatives for Tokyo Legacy Half Marathon
Nutraceuticals
Introducing InnerSignal SC Rich Cream- Regulates moisture in the stratum corneum for a higher level of skin care experience -
September
Pharmaceuticals
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Corporate
Otsuka Pharmaceutical Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers
Pharmaceuticals
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disorders -
August
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan -EXCITING SUMMER in WAJIKI and ORONAMIN C DRINK PRESENTS Awa Odori Sound Festival-
Pharmaceuticals
Astex Expands Drug Discovery Collaboration With MSD
Nutraceuticals
POCARI SWEAT X TOKUSHIMA VORTIS Football Dream Project Phase 3Otsuka Pharmaceutical and Tokushima Vortis collaborate in exchange program for junior football players in Cambodia
July
Nutraceuticals
Launch of TCRP NEXT, a New Collaboration Aiming to Promote Total Conditioning- Enhancing sustainable international competitiveness and transitioning from high performance to life performance -
Pharmaceuticals
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
Corporate
Tokushima Prefecture Signs First Resource Circulation Agreement with Otsuka Pharmaceutical- Promotion of Horizontal PET Bottle Recycling Initiatives -
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreementwith Ministry of the Environment
April
Pharmaceuticals
FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII®(aripiprazole), the First, Two-month, Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
Pharmaceuticals
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia
March
Corporate
Otsuka Holdings Selected as Nadeshiko Brand for FY 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.6 KB)
Nutraceuticals
New SOYJOY Fruits & Cheese Baked cheesecake-flavored whole-soy nutrition bar with ample fruit
Nutraceuticals
Introducing New UL•OS Scalp Shampoo Volume-up Addresses men's scalp condition and hair problems
Nutraceuticals
New EQUELLE gelée , an Extension of the EQUELLE BrandA convenient, smart solution for midlife transitions
February
Nutraceuticals
Otsuka Pharmaceutical an Official Partner of Tokyo Marathon 2023Providing health management support for runners and officials
Corporate
Otsuka Pharmaceutical Finalizes Agreement with Naruto City and Toyota Tsusho Corporation to Promote Horizontal Recycling of PET bottles
Corporate
Otsuka Pharmaceutical Receives "Consumer-oriented Activity Award" at the 8th ACAP Consumer-oriented Activity Awards - Recognized for ongoing women’s health-care initiatives-
January
Corporate
Otsuka Pharmaceutical Installs Solar Power Generation Systems at Takasaki and Tokushima Itano Factories-Targeting reduction of CO2 emissions-
Pharmaceuticals
Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan
Pharmaceuticals
Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology
Pharmaceuticals